Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

Executive Summary

UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.


Related Content

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Payers Want Deep Discounts To Make Biosimilars Worth Their While
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Biosimilar Prescribing Decisions May Depend Upon Disease State
Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts